ArticleEuropean journal of nuclear medicine and molecular imaging2023
Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05728515 (Pilot Clinical Evaluation of a Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Clinical Evaluation of a Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Guideline
- A prospective head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- Diagnostic efficacy of [European journal of nuclear medicine and molecular imaging · 2024Trial
- [European journal of nuclear medicine and molecular imaging · 2026Article
- CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Incidental Detection of a CAIX-avid Breast Invasive Ductal Carcinoma on 68 Ga-NY104 PET/CT During Evaluation of a Suspected Renal Mass.Clinical nuclear medicine · 2026Article
- Carbonic Anhydrase IX-Targeted Molecular Probe for Positron Emission Tomography Imaging of Clear Cell Renal Cell Carcinoma.Chemical & biomedical imaging · 2026Article
- Application of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).Oncology letters · 2026Review
- Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
- Structure-based redesign enables clinical translation of CAIX-targeted theranostics in clear cell renal cell carcinoma.Theranostics · 2026Article
- Article
- Synthesis and Construction of I-124 Labeled Small Molecular Probe for Noninvasive PET Imaging of CAIX Expression.Molecular imaging and biology · 2025Article
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Biomarkers in advanced renal cell carcinoma: current practice and future directions.Current opinion in oncology · 2025Review
- Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy.Diagnostics (Basel, Switzerland) · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.American journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeClear cell renal cell carcinoma (ccRCC) highly expresses carbonic anhydrase IX (CAIX). The purpose of this study was to evaluate
methodsThe in vivo and ex vivo biodistribution of
resultsNY104 can be labeled with high radiochemical yield and purity. It quickly cleared through kidney with α-half-life of 0.15 h. Discernible uptake is noted in the heart, lung, liver, stomach, and kidney. The OS-RC-2 xenograft demonstrated intense uptake 5 min after injection and gradually increased until 3 h after injection with ID%/g of 29.29 ± 6.82. Significant binding was detected using autoradiography on sections of human ccRCC tumor. In the three patients studied,
conclusion
trial registrationThe clinical evaluation part of this study was retrospectively registered at ClinicalTrial.gov (NCT05728515) as NYPILOT on 6 Feb, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.